Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 50Neoplasms 13Neoplasm Metastasis 12Gastrointestinal Stromal Tumors 10Carcinoma, Hepatocellular 7Glioblastoma 5Colonic Neoplasms 5Sarcoma 4Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Liver Neoplasms 3Rhabdomyosarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Advanced Cancer 2Wilms Tumor 1Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solid Tumor 1Sarcoma, Ewing 1

Interventions

Dexamethasone 7Bortezomib 4Lenalidomide 3pomalidomide 2glucarpidase 2Kidney Transplantation 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1osimertinib 1mirabegron 1gamma-Glutamyl Hydrolase 1copanlisib 1carfilzomib 1Zoledronic Acid 1Urinalysis 1Topotecan 1Thalidomide 1Tablets 1Stents 1Sitagliptin Phosphate 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Insufficiency × regorafenib × Clear all
NCT01853046 2017-02-20

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Bayer

Phase 1 Completed
24 enrolled 30 charts

Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡